Equities

Endonovo Therapeutics Inc

ENDV:PKC

Endonovo Therapeutics Inc

Actions
  • Price (USD)0.0008
  • Today's Change0.000 / 14.29%
  • Shares traded540.67k
  • 1 Year change-93.83%
  • Beta-0.6109
Data delayed at least 15 minutes, as of Nov 25 2024 19:54 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Endonovo Therapeutics Inc had net income fall 495.02% from a loss of 3.10m to a larger loss of 18.47m despite a 85.15% increase in revenues from 73.11k to 135.36k.
Gross margin96.21%
Net profit margin-1,722.26%
Operating margin-962.14%
Return on assets-388.54%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2022, cash reserves at Endonovo Therapeutics Inc fell by 85.84k. Cash Flow from Financing totalled 593.00k or 438.09% of revenues. In addition the company used 678.84k for operations while cash used for investing totalled .
Cash flow per share--
Price/Cash flow per share--
Book value per share-0.072
Tangible book value per share-0.0745
More ▼

Balance sheet in USDView more

Endonovo Therapeutics Inc uses little or no debt in its capital structure.
Current ratio0.0015
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.